Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364482 | 1.00 | HTT (0.65) | HTTRECQLMAPTKMT2AMEN1 | |
| SCHEMBL9486033 | 1.00 | HTT (0.65) | HTTRECQLMAPTKMT2AMEN1 | |
| SCHEMBL30269691 | 1.00 | HTT (0.65) | HTTRECQLMAPTKMT2AMEN1 | |
| SCHEMBL1218 | 1.00 | HTT (0.65) | HTTRECQLMAPTKMT2AMEN1 | |
| SCHEMBL6258932 | 0.94 | HTT (0.58) | HTTRECQLMAPTKMT2AMEN1 | |
| SCHEMBL16795470 | 0.94 | HTT (0.58) | HTTRECQLMAPTKMT2AMEN1 | |
| SCHEMBL7368742 | 0.83 | MAPK1 (0.60) | HTTMAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL7368740 | 0.83 | MAPK1 (0.60) | HTTMAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL10036804 | 0.81 | CYP1A1 (0.63) | MAPTKMT2AMEN1CYP1A2CYP1A1 | |
| SCHEMBL166048 | 0.81 | CYP1A1 (0.63) | MAPTKMT2AMEN1CYP1A2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | claimed |
| CN-111440147-A | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2020-07-24 | — | — | CN | claimed |
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| EP-3333162-A1 | METOD FOR PREPARING N-(2-METHYL-5-NITROPHENYL)-4-(PYRIDIN-3-YL)PYRIMIDIN-2-AMINE | Silesian Catalysts sp. z o.o. (PL) | 2018-06-13 | — | — | EP | claimed |
| EP-1833815-B1 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INST FARMACEUTYCZNY (PL) | 2010-09-15 | — | — | EP | claimed |
| US-7674901-B2 | Process for preparation of imatinib base | INSTYTUT FARMACEUTYCZNY (PL) | 2010-03-09 | — | — | US | claimed |
| WO-2010014022-A1 | A PROCESS FOR THE PREPARATION OF IMATINIB | TEMAPHARM SP. Z O.O. (PL) | 2010-02-04 | — | — | WO | claimed |
| US-20080194819-A1 | Process For Preparation of Imatinib Base | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-14 | — | — | US | claimed |
| EP-1833815-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2007-09-19 | — | — | EP | claimed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | claimed |
| WO-2004108699-A1 | PROCESS FOR THE PREPARATION OF THE ANTI-CANCER DRUG IMATINIB AND ITS ANALOGUES | NATCO PHARMA LIMITED (IN) | 2004-12-16 | — | — | WO | claimed |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-3745105-B1 | TEMPERATURE DETECTION LABEL AND ARTICLE MANAGEMENT DEVICE USING SAME | HITACHI LTD (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-20240400247-A1 | TEMPERATURE INDICATOR MANUFACTURING SYSTEM AND TEMPERATURE INDICATOR MANUFACTURING METHOD | HITACHI INDUSTRIAL EQUIPMENT SYSTEMS CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4444289-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-4374988-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4281000-A | Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents | AMERICAN CYANAMID COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| EP-0029103-A1 | 6- and 8-Heteroaryl-1,2,4-triazolo(4,3-b)pyridazines | AMERICAN CYANAMID COMPANY (US) | 1981-05-27 | — | — | EP | disclosed |
| US-4260756-A | TRANQUILIZERS | AMERICAN CYANAMID COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| EP-0025819-A1 | Substituted pyrazolo (1,5-a) pyrimidines, and their preparation | AMERICAN CYANAMID COMPANY (US) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194819-A1 | Process For Preparation of Imatinib Base | ABL1, ABL2, JAK2 | HTT 2724/4885RECQL 2960/4885MAPT 3845/4885 |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | HTT 190/4885RECQL 125/4885MAPT 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.